A brand-new event has just launched in the renowned World ADC Series – the inaugural ADC Payload Summit is taking place this May in Boston (21-23)! The ADC payload landscape is shifting rapidly.

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

Celltrion targets innovative drug development with new ADC and antibody candidates Celltrion aims for growth by venturing ...

NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE: BHVN) and Merus N.V.

Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...

AT03-65 is the first program utilizing AxcynDOT™, a proprietary payload with a differentiated mechanism of action, to enter clinical development AT03-65 is a differentiated ADC that selectively ...

Additionally, over 90 ADC candidates in clinical trials, as of 2023, signal a robust and promising pipeline. Breakthroughs such as bispecific ADCs and combination therapies are paving the way for ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan ...

The FDA has approved Datroway® (datopotamab deruxtecan-dlnk) for adult patients with unresectable or metastatic HR-positive, ...

Axcynsis Therapeutics Pte Ltd ("Axcynsis"), a privately held biopharmaceutical company specialized in delivering Antibody Drug Conjugates (ADCs) with breakthrough potential, proudly announces the ...